Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 1, 2011, Pages 15-23

  Teague, Joanne ^a   Gyte, Amie ^a   Peel, Joanne E ^a   Young, Kimberley C ^a,b   Loxham, Susan J G ^a   Mayers, Rachel M ^a   Poucher, Simon M ^a  

^a ASTRAZENECA   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Disease model; Insulin content; Islet; ZDF rat

Indexed keywords

GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; RAT;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; OBESITY; RATS; RATS, ZUCKER;

ANIMALIA; RATTUS;

EID: 78650777899     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.04.001     Document Type: Article

References (28)

1. Bergeron R., Yao J., Woods J.W., Zycband E.I., Liu C., Li Z., et al. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism. Endocrinology 2006, 147:4252-4262.
2. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
3. Corsetti J.P., Sparks J.D., Peterson R.G., Smith R.L., Sparks C.E. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000, 148:231-241.
4. Deng S., Vatamaniuk M., Huang X., Doliba N., Lian M.M., Frank A., et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004, 53:624-632.
5. Etgen G.J., Oldham B.A. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 2000, 49:684-688.
6. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonard T., et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001, 50:1021-1029.
7. Han M.S., Chung K.W., Cheon H.G., Rhee S.D., Yoon C.H., Lee M.K., et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 2009, 58:329-336.
8. Holman R.R. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Research Clinical Practice 1998, 40(Suppl):S21-S25.
9. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2001, 86:4047-4058.
10. Kaiser N., Yuli M., Uckaya G., Oprescu A.I., Berthault M.F., Kargar C., et al. Dynamic changes in {beta}-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus: Impact of glycemic control. Diabetes 2005, 54:138-145.
11. Kargar C., Ktorza A. Anatomical versus functional beta-cell mass in experimental diabetes. Diabetes, Obesity & Metabolism 2008, 10(Suppl 4):43-53.
12. Kawasaki F., Matsuda M., Kanda Y., Inoue H., Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. American Journal of Physiology. Endocrinology and Metabolism 2005, 288:E510-E518.
13. Kjorholt C., Akerfeldt M.C., Biden T.J., Laybutt D.R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005, 54:2755-2763.
14. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., Turner R.C. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Medicine 1998, 15:297-303.
15. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
16. Nesher R., Gross D.J., Donath M.Y., Cerasi E., Kaiser N. Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 1999, 48:731-737.
17. Paris M., Bernard-Kargar C., Berthault M.F., Bouwens L., Ktorza A. Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats. Endocrinology 2003, 144:2717-2727.
18. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998, 47:358-364.
19. Poitout V., Robertson R.P. Minireview: Secondary beta-cell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
20. Portha B., Lacraz G., Kergoat M., Homo-Delarche F., Giroix M.H., Bailbe D., et al. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?. Molecular and Cellular Endocrinology 2009, 297:73-85.
21. Smith S.A., Lister C.A., Toseland C.D., Buckingham R.E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes, Obesity & Metabolism 2000, 2:363-372.
22. Sturis J., Gotfredsen C.F., Romer J., Rolin B., Ribel U., Brand C.L., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. British Journal of Pharmacology 2003, 140:123-132.
23. Topp B.G., Atkinson L.L., Finegood D.T. Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats. American Journal of Physiology. Endocrinology and Metabolism 2007, 293:E1730-E1735.
24. Tozzo E., Ponticiello R., Swartz J., Farrelly D., Zebo R., Welzel G., et al. The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. The Journal of Pharmacology and Experimental Therapeutics 2007, 321:107-115.
25. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
26. Ullrich S., Wollheim C.B. Islet cyclic AMP levels are not lowered during alpha 2-adrenergic inhibition of insulin release. The Journal of Biological Chemistry 1984, 259:4111-4115.
27. Wargent E., Stocker C., Augstein P., Heinke P., Meyer A., Hoffmann T., et al. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: Comparison with and combination with rosiglitazone. Diabetes, Obesity & Metabolism 2005, 7:170-181.
28. Zhou Y.P., Madjidi A., Wilson M.E., Nothhelfer D.A., Johnson J.H., Palma J.F., et al. Matrix metalloproteinases contribute to insulin insufficiency in Zucker diabetic fatty rats. Diabetes 2005, 54:2612-2619.